Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.

The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One. 2013; 8(3):e58164.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.